Premium
Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites
Author(s) -
Deng Lihui,
Tang Hong
Publication year - 2011
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2011.00873.x
Subject(s) - drug resistance , virology , hepatitis b virus , drug , virus , mutation , resistance mutation , antiviral drug , medicine , hepatitis b , biology , pharmacology , genetics , gene , reverse transcriptase , rna
Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.